Trials / Recruiting
RecruitingNCT06794996
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 67 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inaxaplin | Tablets for Oral Administration. |
Timeline
- Start date
- 2025-02-04
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2025-01-27
- Last updated
- 2026-04-08
Locations
35 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06794996. Inclusion in this directory is not an endorsement.